Abstract
Osteogenesis imperfecta (OI) is a heterogeneous group of congenital disorders characterized by bone fragility and connective tissue abnormalities arising from quantitative or qualitative defects in type I collagen. We present a clinical summary of six patients with OI managed at our institution, highlighting their clinical presentations, genetic subtypes, and therapeutic outcomes. Diagnosis was prompted by a wide range of factors, such as family history, recurrent fractures, blue sclerae, muscle weakness, and suspicion of child abuse. Genetic testing identified five cases of OI caused by pathogenic variants in COL1A1 or COL1A2, which encode type I collagen. Among these, two cases were classified as COL1-related overlap disorders, presenting with features of Ehlers– Danlos syndrome. Additionally, one case of Bruck syndrome type 1 caused by a pathogenic variant in FKBP10 was identified. All patients were treated with cyclic intravenous pamidronate therapy, which was associated with increased bone mineral density and a corresponding reduction in fracture frequency. The primary adverse event was a transient acute-phase reaction characterized by fever following the initial infusion; however, no serious adverse events were observed. Given its diverse clinical features and genetic heterogeneity, OI requires careful differentiation from child abuse and a coordinated multidisciplinary management approach. Although bisphosphonate therapy proved effective and safe in this cohort, continued monitoring for adverse effects and long-term follow-up remain essential.